EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Post the sale, Patel family has become the single largest promoter shareholder in the company
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
To focus on providing safer burn treatments for women and armed forces
EC grants conditional marketing authorization based on the EFFISAYIL trial
This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA
As a result, Imago will become a subsidiary of Merck.
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
The company will set-up a pharmaceuticals formulation manufacturing unit with an investment of Rs. 100 crore in Odisha
Subscribe To Our Newsletter & Stay Updated
